The total return over the past 12 months is -58.22% vs. +16.94% for the S&P 500. So far it's up -63.18% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (58.22%) | +2.45% | (16.35%) | N/A | N/A | N/A |
| Total Return CAGR | (58.22%) | +2.45% | (16.35%) | N/A | N/A | N/A |
| Revenue CAGR | +4.08% | +710.87% | +36.43% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
ARS Pharmaceuticals, Inc. (SPRY)
| Year | Start price | End price | SPRY Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $11.65 | $4.29 | (63.18%) | +14.51% | (77.69%) |
| 2025 | $10.55 | $11.65 | +10.43% | +17.72% | (7.29%) |
| 2024 | $5.48 | $10.55 | +92.52% | +24.89% | +67.63% |
| 2023 | $8.53 | $5.48 | (35.76%) | +26.19% | (61.95%) |
| 2022 | $6.66 | $8.53 | +28.08% | (18.17%) | +46.25% |
| 2021 | $46.34 | $6.66 | (85.63%) | +28.74% | (114.37%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
